Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunitybio Inc
(NQ:
IBRX
)
5.490
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
29,499
Open
5.490
Bid (Size)
5.310 (22)
Ask (Size)
5.350 (1)
Prev. Close
5.490
Today's Range
5.490 - 5.490
52wk Range
1.250 - 6.780
Shares Outstanding
391,156,513
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
April 23, 2024
FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. Anktiva shows promising complete response rates and duration exceeding 24...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 23, 2024
Via
Benzinga
Performance
YTD
+4.77%
+4.77%
1 Month
+0.92%
+0.92%
3 Month
+63.39%
+63.39%
6 Month
+205.00%
+205.00%
1 Year
+125.00%
+125.00%
More News
Read More
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
April 23, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 23, 2024
Via
InvestorPlace
ImmunityBio: Q4 Earnings Insights
March 19, 2024
Via
Benzinga
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 22, 2024
From
ImmunityBio, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
March 20, 2024
Via
Benzinga
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
March 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
March 19, 2024
Via
InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
Via
FinancialNewsMedia
5 Stocks with Unusually Large Short Interest
March 08, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
March 06, 2024
From
ImmunityBio
Via
Business Wire
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
March 05, 2024
From
ImmunityBio
Via
Business Wire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
February 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 26, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 26, 2024
Via
InvestorPlace
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
February 26, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 23, 2024
Via
Benzinga
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
February 21, 2024
From
ImmunityBio
Via
Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
February 05, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 23, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
